Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and/or Refractory Multiple Myeloma (RRMM)”

79 trials

Showing 20 of 79 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT05909826
What this trial is testing

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Dong-A University Hospital 49
Not applicableUnknownNCT05297240
What this trial is testing

Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

Who this might be right for
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
PETHEMA Foundation 170
Testing effectiveness (Phase 2)Looking for participantsNCT07266441
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 157
Testing effectiveness (Phase 2)Looking for participantsNCT06484829
What this trial is testing

Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Chengdu Zenitar Biomedical Technology Co., Ltd 144
Large-scale testing (Phase 3)Active Not RecruitingNCT05552976
What this trial is testing

Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb 525
Not applicableActive Not RecruitingNCT04458831
What this trial is testing

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Plasma Cell Myeloma
Sanofi 583
Testing effectiveness (Phase 2)Study completedNCT02046070
What this trial is testing

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 148
Testing effectiveness (Phase 2)WithdrawnNCT05647512
What this trial is testing

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Who this might be right for
Relapsed or Refractory Multiple MyelomaOther Plasma Cell Diseases
LaNova Medicines Limited
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07348393
What this trial is testing

A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Assistance Publique - Hôpitaux de Paris 70
Testing effectiveness (Phase 2)Looking for participantsNCT06106945
What this trial is testing

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AstraZeneca 226
Early research (Phase 1)WithdrawnNCT05918250
What this trial is testing

MRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
Early research (Phase 1)Study completedNCT03650491
What this trial is testing

FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma With Failed Remission
Fortis Therapeutics, Inc. 31
Large-scale testing (Phase 3)Ended earlyNCT03151811
What this trial is testing

Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

Who this might be right for
Multiple Myeloma
Oncopeptides AB 495
Testing effectiveness (Phase 2)Study completedNCT05014412
What this trial is testing

Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

Who this might be right for
Multiple Myeloma
Pfizer 86
Early research (Phase 1)Looking for participantsNCT06644118
What this trial is testing

OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Zhejiang University 58
Testing effectiveness (Phase 2)Study completedNCT02045017
What this trial is testing

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Who this might be right for
Multiple Myeloma
Celgene 81
Not applicableStudy completedNCT05217082
What this trial is testing

A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 35
Testing effectiveness (Phase 2)Study completedNCT04191616
What this trial is testing

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Amgen 54
Testing effectiveness (Phase 2)WithdrawnNCT05408026
What this trial is testing

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Testing effectiveness (Phase 2)Ended earlyNCT04776018
What this trial is testing

TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda 27
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation